But senior Trump administration officials on Thursday downplayed the risk of delays, citing a confusion over semantics, while Pfizer said its production levels have not changed.
In recent days, governors and health leaders in at least 10 states have said the federal government has told them that next week’s shipment of the Pfizer-BioNTech vaccine will be less than originally projected.
Little explanation was offered, leaving many state officials perplexed.
“This is disruptive and frustrating,” Washington Gov. Jay Inslee, a Democrat, wrote on Twitter Thursday after learning from the Centers for Disease Control and Prevention that the state’s allocation would be cut by 40%. “We need accurate, predictable numbers to plan and ensure on-the-ground success.”
California, where an explosion in cases is straining intensive care units to the breaking point, will receive 160,000 fewer vaccine doses than state officials had anticipated next week — a roughly 40% reduction.
California hospitals began vaccinations this week from the first Pfizer shipment of 327,000 doses and had expected even more to arrive next week. Instead, officials have been told to expect about 233,000 doses, said Erin Mellon, a spokeswoman for Gov. Gavin Newsom.
Missouri’s health director, Dr. Randall Williams, said his state will get 25% to 30% less of the vaccine next week than anticipated. A statement from the Iowa Department of Public Health said its allocation will be “reduced by as much as 30%, however we are working to gain confirmation and additional details from our federal partners.”
Michigan’s shipment will drop by about a quarter. Illinois, Montana, Kansas, Nebraska, New Hampshire and Indiana also have been told to expect smaller shipments.
In Washington, D.C., two senior Trump administration officials who spoke on condition of anonymity to discuss internal planning said states will receive their full allocations, but misunderstandings about vaccine supply and changes to the delivery schedule may be creating confusion.
One official said the initial numbers of available doses that were provided to states were projections based on information from the manufacturers, not fixed allocations. Some state officials may have misunderstood that, the official said.
The two officials also said that changes the federal government made to the delivery schedule, at the request of governors, may be contributing to a mistaken impression that fewer doses are coming. The key change involves spacing out delivery of states’ weekly allocations over several days to make distribution more manageable.
“They will get their weekly allocation, it just won’t come to them on one day,” one official said.
Pfizer made it clear that as far as production goes, nothing has changed.
“Pfizer has not had any production issues with our COVID-19 vaccine, and no shipments containing the vaccine are on hold or delayed,” spokesman Eamonn Nolan said in an email. “We are continuing to dispatch our orders to the locations specified by the U.S. government.”
The company said in a written statement that this week it “successfully shipped all 2.9 million doses that we were asked to ship by the U.S. Government to the locations specified by them. We have millions more doses sitting in our warehouse but, as of now, we have not received any shipment instructions for additional doses.”
The senior administration officials said Pfizer’s statement about doses awaiting shipping instructions, while technically accurate, conveniently omits the explanation: It was planned that way.
The federal officials said Pfizer committed to provide 6.4 million doses of its vaccine in the first week after approval. But the federal Operation Warp Speed had already planned to distribute only 2.9 million of those doses right away. Another 2.9 million were to be held at Pfizer’s warehouse to guarantee that individuals vaccinated the first week would be able to get their second shot later to make protection fully effective. Finally, the government is holding an additional 500,000 doses as a reserve against unforeseen problems.
Pfizer said it remains confident it can deliver up to 50 million doses globally this year and up to 1.3 billion doses in 2021.
Alonso-Zaldivar contributed from Washington, D.C. Rachel La Corte in Olympia, Washington, contributed to this report.